Full Press Release Details
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) --Krystal Biotech, Inc.(the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at:https://www.webcaster5.com/Webcast/Page/3018/53916.
For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website atwww.krystalbio.com.
About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visithttp://www.krystalbio.com, and follow @KrystalBiotech onLinkedInandX(formerly Twitter).